AutoPiX is a major international project focused on improving healthcare for people with rheumatic and musculoskeletal diseases (RMDs).
The AutoPiX project brings together pharmaceutical and medical technology partners with leading academic institutions to enhance the use of imaging biomarkers for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), collectively known as systemic arthritides.
It aims to develop advanced imaging tools and artificial intelligence (AI) models to better diagnose, monitor, and treat these conditions. These tools will make use of imaging biomarkers—like X-rays, ultrasounds, and MRIs—to provide more precise and personalised care.
Novartis is an innovative medicines company. Our purpose is to reimage medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide, focusing on therapeutic areas with high unmet patient needs and technology platforms that enable cutting-edge innovative therapies.
